Lixte Biotechnology Holdings Inc - Asset Resilience Ratio
Lixte Biotechnology Holdings Inc (LIXTW) has an Asset Resilience Ratio of 45.17% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Lixte Biotechnology Holdings Inc total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2009–2012)
This chart shows how Lixte Biotechnology Holdings Inc's Asset Resilience Ratio has changed over time. See Lixte Biotechnology Holdings Inc (LIXTW) shareholders funds for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Lixte Biotechnology Holdings Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Lixte Biotechnology Holdings Inc market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $2.45 Million | 45.17% |
| Total Liquid Assets | $2.45 Million | 45.17% |
Asset Resilience Insights
- Very High Liquidity: Lixte Biotechnology Holdings Inc maintains exceptional liquid asset reserves at 45.17% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Lixte Biotechnology Holdings Inc Industry Peers by Asset Resilience Ratio
Compare Lixte Biotechnology Holdings Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Lixte Biotechnology Holdings Inc (2009–2012)
The table below shows the annual Asset Resilience Ratio data for Lixte Biotechnology Holdings Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2012-12-31 | 0.35% | $6.13K | $1.75 Million | -82.55pp |
| 2010-12-31 | 82.90% | $1.60 Million | $1.93 Million | +81.34pp |
| 2009-12-31 | 1.56% | $25.00K | $1.60 Million | -- |
About Lixte Biotechnology Holdings Inc
Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubi… Read more